A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs AMP 514 (Primary) ; Durvalumab (Primary) ; Nivolumab
- Indications Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 14 Oct 2019 Planned End Date changed from 15 Jul 2019 to 31 Mar 2020.
- 14 Oct 2019 Planned primary completion date changed from 15 Jul 2019 to 31 Mar 2020.
- 20 Mar 2019 Planned End Date changed from 18 Mar 2021 to 15 Jul 2019.